7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

NeuroSense Therapeutics Ltd.
(NASDAQ:NRSN) 

NRSN stock logo

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin an...

Founded: 2017
Full Time Employees: 11
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
NeuroSense Therapeutics . Op Cashflow Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.25-0.21-0.18-0.14-0.11-0.07-0.030
NeuroSense Therapeutics . Free Cashflow Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.25-0.21-0.18-0.14-0.11-0.07-0.040
NeuroSense Therapeutics . Cash Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.250.510.761.011.271.521.77
NeuroSense Therapeutics . (GAAP) P/E ratio ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -1,946.23-1,668.2-1,390.17-1,112.13-834.1-556.07-278.030
NeuroSense Therapeutics . P/B ratio ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -130.37-110.95-91.53-72.12-52.7-33.28-13.875.55
No extra charts and metrics for this ticker.